---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-057516"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:10:49.015308+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# uniQure Q1 net loss $77.2M ($1.63/shr); cash $315.3M; on track for AMT-130 data Q2

## Summary
- Revenue $5.3M (up from $1.8M YoY) on $4.9M contract manufacturing for HEMGENIX.
- Eligible for $100M milestone from CSL on first US commercial sale of HEMGENIX; $75M European milestone by July 2, 2023.
- Huntington's disease AMT-130: 1-2 year follow-up data from US Phase I/II expected Q2 2023; higher-dose enrollment in EU trial to complete mid-2023.
- Pipeline advancing: AMT-162 (SOD1-ALS) Phase I/II start H2 2023; AMT-260 (epilepsy) and AMT-191 (Fabry) IND filings in 2023.
- Cash $315.3M expected to fund operations into 2025 ($100M milestone assumed) or H1 2025 if $75M European milestone achieved.

## SEC filing metadata
- accession: 0001104659-23-057516
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465923057516/0001104659-23-057516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465923057516/tm2315123d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-057516
- JSON: https://secwatch.observer/filing/0001104659-23-057516.json
- Plain text: https://secwatch.observer/filing/0001104659-23-057516.txt

## Key facts
- Earnings Releases
  uniQure N.V. reported the first quarter of 2023 results: revenue $5.3 million.
  - Period: the first quarter of 2023
  - Revenue: $5.3 million
  - Result: reported results
  source text: Revenue for the three months ended March 31, 2023 was $5.3 million, compared to $1.8 million in the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590560/000110465923057516/0001104659-23-057516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.